Correlation between enhancement of graft-versus-leukemia effects following allogeneic bone marrow transplantation by rIL-2 and increased frequency of cytotoxic T-lymphocyte precursors in murine myeloid leukemia

Cytokines, Cellular and Molecular Therapy

Volumn 6, Issue 3, 2000, Pages 141-147

  Leshem, B ^a   Vourka Karussis, U ^a   Slavin, S ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Allogeneic cell therapy; Bone marrow transplantation (BMT); CTL; Graft versus leukemia (GVL); rIL 2

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOIMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOTOXIC T LYMPHOCYTE; GRAFT VERSUS LEUKEMIA EFFECT; IRRADIATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROLYMPHOCYTE; RECIPIENT; SPLEEN CELL;

EID: 0034486058     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: 10.1080/mccm.6.3.141.147     Document Type: Article

References (37)

1. Antileukemia effect of graft-versus-host disease human recipients of allogeneic marrow grafts
2. Graft-versus-leukemia reactions in humans
3. Graft-versus-leukemia reactions after bone marrow transplantation
4. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemia relapse
5. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes
6. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation
7. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI)
8. Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-versus-leukemia activity in vivo
9. Possibility of graft-vs-leukemia determinants independent of the major histocompatibility complex in allogeneic marrow transplantation
10. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation
11. Effective graft vs leukemia effects independent of graft vs host disease after T-cell depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role at cell therapy and IL-2
12. Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells
13. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities
14. The graft-versus-leukemia (GVL) phenomenon: Is GVL separable from GVHD?
15. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects
16. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allegeneic bone marrow transplantation
17. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation
18. Lymphokine-activated killer cell plus recombinant interleukin-2 therapy of erythroleukemia in mice
19. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematological disorders
20. Immunotherapy with recombinant human interleukin-2 (IL-2) and recombinant α-interferon in lymphoma patients post autologous marrow or stem cell transplantation
21. High incidence of acute myeloid leukemia in SJL/J mice after X-irradiation and corticosteroids
22. Cell mediated cytotoxicity, allograft rejection, and tumor immunity
23. Quantitation and cloning of cytotoxic T lymphocytes and their precursors
24. In vitro elicitation of cytotoxic response against a nonimmunogenic murine tumor by allosensitization
25. Cytotoxic T lymphocytes reactive against a syngeneic murine tumor and their specific suppressor T cells are both elicited by in vitro allosensitization
26. Graft-versus-leukemia following allogeneic bone marrow transplantation: Emergence of cytotoxic T lymphocytes reacting to host leukemia cells
27. Lethal GVHD, across minor histocompatibility barriers: Nature of the effector cells and role of the H-2 complex
28. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-vs-leukemia without myeloablative therapy
29. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases
30. Characterization of effector cells of graft vs leukemia (GVL) following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia (BCL1)
31. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow
32. Allosensitization in IL-2 containing limiting dilution cultures generates cytotoxic T lymphocytes rather than LAK cells reactive with a syngeneic nonimmunogenic murine tumor
33. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL2-activated cell-mediated immunotherapy
34. Dissociating graft vs host disease from the graft vs leukemia effect of allogeneic T cells: The potential role of IL-2
35. Induction of preferential cytotoxicity against allogeneic mouse lymphoma cells: In vitro and in vivo studies
36. Adoptive immunotherapy in conjunction with bone marrow transplantation - Amplification of natural host defence mechanisms against cancer by recombinant IL2
37. Induction of graft vs leukemia effects by cell-mediated lymphokine activated immunotherapy after syngeneic BMT in murine B-cell leukemia